Yesterday, the EIC announced that Gedea Biotech has been selected for the €2.5M EIC Accelerator grant for the continued development and commercialization of p Hyph, an antibiotic free treatment for vaginal infections. The funding will accelerate the development of p Hyph, bringing this treatment earlier to patients in need. The EIC Accelerator is the most competitive program of its kind in Europe – for the November 2023 cutoff only 42 out of 1083 (~4%) applicants were selected for funding. The final decision was taken by a highly experienced jury who verified the uniqueness and commercial potential of p Hyph. Gedea applied for the EIC grant to accelerate the development of Gedea’s lead product p Hyph via clinical validation and regulatory approval process – together with initial go-to-market steps. The formal EU Grant Agreement preparation process has already been initiated. p Hyph is a global breakthrough antibiotic-free treatment for both bacterial and fungal vaginal infections that affect >400 million women every year. Current treatments have numerous side effects, high risk of recurrence and can lead to development of antimicrobial resistance. p Hyph has shown a clinical cure rate for bacterial vaginosis in line with antibiotics on the market, with a superior safety profile and without causing secondary VVC infections, a common side effect of antibiotics. The results for fungal vaginal infections are promising. Being selected in this highly competitive EIC Accelerator process is yet another proof of the importance of supporting women’s health and a quality stamp of our work in developing antibiotic-free treatment options for common female infections, says Annette Säfholm, CEO of Gedea Biotech. The funding will strengthen Gedea and allow us to support our “go-to-market” efforts in all aspects of p Hyph development.” says Annette Säfholm. Today, I am extremely proud of the team, the support from our investors and of our achievements and I am particularly grateful that the EIC has recognized Gedea’s ability to support the development of an antibiotic-free treatment option ̵ thereby fighting overall antimicrobial resistance (AMR).” says Ton Berkien, Chairman of the Board.
This content was originally published here.
